Screener
Eli Lilly LLY Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Assets | June 30, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt | $7,050 | $1,635 |
| Accounts payable | 6,112 | 5,379 |
| Employee compensation | 1,798 | 2,375 |
| Sales rebates and discounts | 21,122 | 17,382 |
| Other current liabilities | 11,659 | 8,457 |
| Total current liabilities | 47,741 | 35,228 |
| Noncurrent Liabilities |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's accrued manufacturing costs?
- Eli Lilly (LLY) reported accrued manufacturing costs of $1.8B in Q2 2026.
- How has Eli Lilly's accrued manufacturing costs changed year-over-year?
- Eli Lilly's accrued manufacturing costs increased by 38.0% year-over-year, from $1.3B to $1.8B.
- What is the long-term trend for Eli Lilly's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Eli Lilly's accrued manufacturing costs has grown at a 19.0% compound annual growth rate (CAGR), from $997.2M to $2.38B.
- What does accrued manufacturing costs mean?
- Accrued liabilities related to manufacturing and production activities.
Ask your AI about Eli Lilly's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude